Laurus Labs has been granted a patent for an improved process to prepare dapagliflozin, a sodium-dependent glucose transporter inhibitor used in diabetes treatment. The invention includes novel intermediates and outlines specific methods for synthesizing dapagliflozin and its solvates or co-crystals. GlobalData’s report on Laurus Labs gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Laurus Labs, Peptide pharmacophores was a key innovation area identified from patents. Laurus Labs's grant share as of July 2024 was 62%. Grant share is based on the ratio of number of grants to total number of patents.
Improved process for preparing dapagliflozin and its derivatives
The granted patent US12071418B2 outlines a comprehensive process for the preparation of dapagliflozin, a medication used primarily for the treatment of type 2 diabetes. The claims detail various steps and conditions involved in synthesizing dapagliflozin, including the selection of specific chemical groups, protecting groups, leaving group sources, and amine sources. Notably, the process allows for the use of a wide range of solvents, bases, and glycosidation reagents, providing flexibility in the synthesis. The claims also specify the use of various reducing agents and acids in the reduction step, emphasizing the versatility of the method in producing dapagliflozin and its derivatives.
Additionally, the patent includes claims for the preparation of pharmaceutical formulations containing dapagliflozin or its solvates and co-crystals, highlighting the integration of the synthesized compound into a usable medication form. The claims specify that the formulation process involves combining dapagliflozin with at least one pharmaceutically acceptable excipient, ensuring that the final product meets the necessary standards for therapeutic use. Overall, the patent presents a detailed and methodical approach to the synthesis and formulation of dapagliflozin, which may contribute to advancements in diabetes treatment.
To know more about GlobalData’s detailed insights on Laurus Labs, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
